
Elicera Therapeutics (Q3 Review) - Entering a Catalyst-Dense Phase

Redeye returns with an update following Elicera's Q3 earnings release. The numbers offered few surprises, which is typical for a pre-revenue biotech. What stands out is the busy period ahead, with two clinical data readouts expected over the next five months.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Elicera Therapeutics (Q3 Review) - Entering a Catalyst-Dense Phase